נתוני תרופה
במרשם
| מינונים נוספים
|
|
| קבוצה פרמקולוגית (ATC4)
|
L01XC
Monoclonal antibodies
|
| מרכיב פעיל (ATC5)
|
*Trastuzumab 440MG/ML L01XC03
- Trastuzumab 440MG/ML L01XC03
- Monoclonal antibodies L01XC L01XC03
- 7290008140478 לא L01XC03
- 1 dna way,south san francisco,california bulk production , filling of powder L01XC03
- 4625 nw brookwood parkway, hillsboro or, 97124-9332, USA filling of powder , bulk production L01XC03
- 1000 new horizon way,vacaville,ca, usa active substance production L01XC03
- Grenzacherstrasse 124, CH-4070 BASEL , SWITZERLAND release , filling of solvent , bulk of solvent L01XC03
- Wurmisweg 232, CH-4303, KAISERAUSGT, SWITZERLAND secondary packing of solvent , secondary packing of powder , filling of solvent , bulk of solvent L01XC03
- 10 taus bay link. singapore 637394, SINGAPORE active substance production L01XC03
- Trastuzumab 440MG/ML L01XC03
|
| צורת מתן
|
I.V
|
| צורת מינון
|
SOLUTION FOR INFUSION
|
| התוויה
|
Herceptin is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress HER2:
- As a single agent for the treatment of those patients who have received one or more chemotherapy regiments for their metastatic disease.
- In combination with Paclitaxel or Docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease.
- Herceptin in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive metastatic breast cancer. Early breast cancer (EBC) :Herceptin is indicated to treat patients with HER2-positive early breast cancer following surgery and chemotherapy (neoadjuvant or adjuvant) either alone or in combination with chemotherapy excluding Anthracyclines. Herceptin should only be used in patients whose tumors have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.HER2 metastatic gastric cancer (mGC)Herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of patients with HER2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.Herceptin should only be used in patients with metastatic gastric cancer whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory FISH+ result, or IHC 3+, as determined by an accurate and validated assay
|
| תבנית:נתוני סל/תרופה/הרספטין 440 מ"ג - Herceptin vials 440 mg
|
| תופעות לוואי
|
Undesirable effects
|
| עלון לרופא והחמרות לעלון
|
החמרה לעלון
|
| חיפוש מאמרים
|
-
|
| מידע ברשת
|
-
|
| שם יצרן
|
HOFFMANN LA ROCHE, SWITZERLAND
|
| שם בעל הרישום
|
ROCHE PHARMACEUTICALS (ISRAEL) LTD
|
| רישיון
|
תאריך הגשה: 03/1999. רישיון מתאריך: 05/2014
|
תמונת אריזה
תאריך עדכון: 14/05/19
הרספטין - Herceptin
true
דף זה נוצר על ידי בוט ומגדיר תבנית עם פרטי התרופה.
{{תרופה/הרספטין 440 מ"ג - Herceptin vials 440 mg}}
ב:
{{תרופה/הרספטין 440 מ"ג - Herceptin vials 440 mg
| שם הפרמטר=ערך חדש (דורס את הערך שהבוט הגדיר)
}}
השינוי האחרון נעשה בֹ־14 במאי 2019 ב־17:28
